Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Prostate cancer (PCa) growth is typically driven by the androgen receptor (AR) signaling axis.
• Current therapies aim to inhibit AR signaling, but paradoxically, high-dose androgens can be effective in late-stage PCa.
• The dual role of androgens in PCa necessitates a deeper understanding of AR signaling dynamics.

Purpose of the Study:

• To investigate the distinct mechanisms by which low and high doses of androgens affect prostate cancer cell proliferation.
• To elucidate the role of androgen receptor (AR) monomer versus dimer/oligomer formation in mediating these effects.
• To identify novel therapeutic targets and strategies for prostate cancer and other androgen-related disorders.

Main Methods:

• Analysis of androgen receptor (AR) signaling pathways under varying androgen concentrations.
• Investigation of non-genomic and genomic activation pathways.
• Assessment of cell proliferation, gene expression (e.g., c-MYC), and AR conformational states (monomer vs. dimer/oligomer).

Main Results:

• Low androgen levels promote PCa proliferation through AR monomer-mediated, non-genomic activation of the mTOR pathway.
• High androgen doses induce AR dimer/oligomer formation, leading to c-MYC suppression, proliferation inhibition, and a differentiated transcriptional program.
• These findings reveal distinct AR signaling outcomes dependent on androgen dose and AR conformation.

Conclusions:

• Current therapeutic strategies targeting AR inhibition may have inherent limitations due to the complex, dose-dependent actions of androgens.
• Understanding AR monomer and dimer/oligomer functions offers new avenues for developing targeted therapies for prostate cancer.
• This research provides critical insights into androgenopathies and informs the development of novel treatment modalities.